Literature DB >> 17072721

Predicting the antitumor effects of STI571 by analysis of c-kit gene mutations in gastrointestinal stromal tumors of the stomach: Report of a case.

Noritsugu Tsuneoka1, Tamotsu Kuroki, Masashi Haraguchi, Jyunichirou Furui.   

Abstract

We report a case of a large gastrointestinal stromal tumor (GIST), greater than 5 cm in diameter, in the stomach. Microscopically, high levels of mitosis were observed, indicative of a high-grade malignancy. We analyzed the c-kit gene mutations by a replication competent retrovirus assay and DNA sequencing, which revealed a c-kit mutation in exon 11. Liver metastases were detected 7 months after surgery. Patients with an exon 11 mutation of the c-kit gene are reported to have a high response to STI571 (imatinib mesylate, Glivec). Accordingly, a 1-month course of STI571 treatment clearly changed the characterization of the metastatic tumors radiographically. Thus, it may be important to analyze c-kit gene mutations in patients presenting with GISTs to predict the effectiveness of STI571 in suppressing GISTs, especially tumors thought to have malignant potential.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17072721     DOI: 10.1007/s00595-006-3288-4

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  14 in total

1.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

Authors:  H Joensuu; P J Roberts; M Sarlomo-Rikala; L C Andersson; P Tervahartiala; D Tuveson; S Silberman; R Capdeville; S Dimitrijevic; B Druker; G D Demetri
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

2.  Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors.

Authors:  C A Moskaluk; Q Tian; C R Marshall; C A Rumpel; D W Franquemont; H F Frierson
Journal:  Oncogene       Date:  1999-03-11       Impact factor: 9.867

3.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

Authors:  S Hirota; K Isozaki; Y Moriyama; K Hashimoto; T Nishida; S Ishiguro; K Kawano; M Hanada; A Kurata; M Takeda; G Muhammad Tunio; Y Matsuzawa; Y Kanakura; Y Shinomura; Y Kitamura
Journal:  Science       Date:  1998-01-23       Impact factor: 47.728

4.  Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall.

Authors:  P Pauwels; M Debiec-Rychter; M Stul; I De Wever; A T Van Oosterom; R Sciot
Journal:  Histopathology       Date:  2005-07       Impact factor: 5.087

Review 5.  Imatinib mesylate: a molecularly targeted therapy for gastrointestinal stromal tumors.

Authors:  Burton L Eisenberg
Journal:  Oncology (Williston Park)       Date:  2003-11       Impact factor: 2.990

6.  Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors.

Authors:  Samuel Singer; Brian P Rubin; Marcia L Lux; Chang-Jie Chen; George D Demetri; Christopher D M Fletcher; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2002-09-15       Impact factor: 44.544

7.  Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?

Authors:  Courtney L Scaife; Kelly K Hunt; Shreyaskumar R Patel; Robert S Benjamin; Michael A Burgess; Lei L Chen; Jonathan Trent; A Kevin Raymond; Janice N Cormier; Peter W T Pisters; Raphael E Pollock; Barry W Feig
Journal:  Am J Surg       Date:  2003-12       Impact factor: 2.565

8.  Clinical management of gastrointestinal stromal tumors: before and after STI-571.

Authors:  Ronald P Dematteo; Michael C Heinrich; Wa'el M El-Rifai; George Demetri
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

Review 9.  Diagnosis of gastrointestinal stromal tumors: A consensus approach.

Authors:  Christopher D M Fletcher; Jules J Berman; Christopher Corless; Fred Gorstein; Jerzy Lasota; B Jack Longley; Markku Miettinen; Timothy J O'Leary; Helen Remotti; Brian P Rubin; Barry Shmookler; Leslie H Sobin; Sharon W Weiss
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

10.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.